COVID-19 Virus: Vitalograph Statement

Message from our CEO Frank Keane


As the COVID-19 (SARS-CoV-2) virus situation continues to cause global disruption, we continue to monitor the effect this may have on our business worldwide. Vitalograph’s manufacturing site is based in Ireland and has experienced little or no disruption to output during the pandemic and we are not experiencing any unmanageable supply chain disruption due to Covid-19. As a global company, we have warehouses in multiple countries holding adequate levels of stock to meet current, and anticipated, customer needs. We also have a wide range of products allowing a supply of alternative items should short term stock issues arise.


Travel restrictions both intra and internationally, are very fluid and dynamic but are not overly affecting us as our respiratory diagnosis focus is viewed as an essential business in all our operating countries. We are prepared for this and our ongoing Business Continuity Plan (BCP) measures, invoked at all sites in the middle of February 2020, include remote working, staggered breaks and dispersed workforce. We practice a robust BCP process, aligned to ISO 22301, tested regularly at all sites. None of our sites has had to close to date and it is business as usual.

Our employees have started to get vaccinated in several of our operating countries and we expect to have most of our global workforce vaccinated by mid-summer. Whilst there has been much media comment on the rollout of the vaccines, we fully recognise the unprecedented effort all vaccine providers and governments have expended to get us to this point. We will continue to practice our mitigation measures until such time as the Covid-19 threat has greatly receded.


Our Company Mission is “To improve patient lives through supporting our customers and partners by designing and manufacturing market leading products and services”. This is a mission we take very seriously, and our employees live and breathe it on a daily basis. Due to the respiratory effects of COVID-19 we are doubling our efforts to ensure we can fulfil our mission and help those in most need at this time.


Regards

Frank Keane CEO

 

Related Articles

We are excited to launch the next generation Pneumotrac spirometer into the US market. The new Vitalograph Pneumotrac™ Spirometer, combined with Spirotrac® PC software, is a powerful tool for respiratory diagnosis of both adults and pediatrics.
We are happy to announce the launch of the next generation Spirotrac®6 PC software which provides a powerful respiratory diagnostic platform. This redesigned software is compliant with 2019 ATS/ERS spirometry guidelines, meeting international guidelines on accuracy and reporting.
Welcome to the new look Vitalograph.com website, designed to provide our US customers with easy access to the information and products they know and trust. Split into Healthcare and Clinical Trials, our new website is intended to compliment our service to you.